



Plot 16, Akanni Doherty Layout (Billings Way), Oregon Ind. Estate, Oregon,
P.M.B. 21111, Ikeja, Lagos State, Nigeria.
Telephone: +2348054431508, +2349030576286,
+2348162465756, +2349042725207
E-mail: info@neimethplc.com.ng
Website: www.neimethplc.com.ng



Lagos, Nigeria 26th June 2026

NEIMETH INTERNATIONAL PHARMACEUTICALS PLC – RESOLUTIONS PASSED AT THE 67TH ANNUAL GENERAL MEETING OF THE COMPANY

At the 67th Annual General Meeting of Neimeth International Pharmaceuticals Plc. held virtually on Thursday, 25th June 2026 at 11.00am, the following resolutions were proposed and duly passed:

ORDINARY BUSINESS

1. That the Audited Financial Statements for the year ended 31st December 2025, Report of the Directors, External Auditors and Statutory Audit Committee thereon be received.
2. That the appointment of Pharm. Obinna S. Emeribe as a Director of the Company be ratified.
3. That Mr. Christopher Oshiafi, Mrs. Henrietta I. Orjiako and Mr. Eric Okoruwa be re-elected as Directors of the Company.
4. That the Directors be authorized to fix the remuneration of the Auditors for the financial year ending 31st December 2026.
5. That the remuneration of managers of the Company in accordance with Section 257 of CAMA be noted.
6. That Dr. Marcel Ojinka, Alhaji Mustapha Jinadu and Mr. Kolawole Kalejaiye be elected as Representatives of Shareholders on the Statutory Audit Committee, while Mazi Samuel Ohuabunwa and Dr. Olusegun Akanji represent the Board on the Statutory Audit Committee until the next Annual General Meeting of the Company.

SPECIAL BUSINESS

7. That the remuneration of the Non-Executive Directors of the Company for the financial year ending 31st December 2026 be approved.
8. That whereas by a resolution dated June 23, 2025, the Company had obtained shareholders' approval to raise capital up to ₦20,000,000,000.00 (Twenty Billion Naira) ("the Existing Approval") pursuant to which the Company has raised approximately ₦2,440,000,000 (Two Billion, Four Hundred and Forty Million Naira) by way of Rights Issue, leaving an unutilised balance of approximately ₦17,560,000,000 (Seventeen Billion, Five Hundred and Sixty Million Naira). The shareholders approved as additional to the unutilised balance of the Existing Approval, the resolutions below:
 - a. That the Board of Directors ("the Board") be and are hereby authorized to raise additional capital of up to ₦30,000,000,000 (Thirty Billion Naira) through an issuance of shares (to be issued, whether by way of public offering, rights issue, private/special placement to strategic or identified investors), commercial papers, bonds, convertible and non-convertible securities), medium term notes and/or any other instruments, either as a stand-alone or by way of programmes, in such tranches, series or proportions, at such coupon or interest rates, within such maturity periods, or on such terms and conditions, through a combination of methods or processes, all of which shall be based on terms and conditions to be determined by the Board and subject to obtaining the approvals of the relevant regulatory authorities;

ncp® **Disinfectant Spray**
...KILLS GERMS INSTANTLY!!!



- Pleasant Fragrance.
- Effectively kills 99.99% of Bacteria and Viruses on Surfaces and Environments.
- Non-Bleach.
- No-Stain.

Board of Directors

Mr. Christopher Oshiafi (Chairman), Pharm. Valentine C. Okelu (MD/CEO), Mrs. Henrietta I. Orjiako, Mazi Sam I. Ohuabunwa (OFR), Prof. Maurice M. Iwu, Sir Ike T. Onyechi, Dr. Olusegun E. Akanji, Dr. (Mrs.) Atinuke R. Uwajeh, Pharm. Obinna S. Emeribe (Exec.), Mr. Eric E. Okoruwa, Mr. Adeyemi O. Odusanya, Mrs. Patricia O. Aderibigbe

- b. That the aggregate shareholders' approval for capital raising shall accordingly be N50,000,000,000 (Fifty Billion Naira), of which approximately N2,440,000,000 has already been raised by way of Rights Issue, leaving an unutilized balance of approximately N47,560,000,000 (Forty Seven Billion, Five Hundred and Sixty Million Naira) available for raising;
- c. That any public offering and rights issue by the Company from the additional capital raise contemplated in Paragraph 8a above be underwritten by an appointed underwriter on a standby basis, to ensure full subscription of the public offering and rights issue, and in the event of an under subscription of any rights issue undertaken by the Company, the Shareholders hereby waive their pre-emptive rights to any unsubscribed shares under the rights issue, and the Board is hereby authorized to issue such shares to interested investors, as far as practicable, on the same terms as the rights issue;
- d. The Board be and is hereby authorized to enter into any agreements and/or approve, sign and/or execute any other documents necessary for and/or incidental to effecting the resolutions above; and
- e. That the Board be and is hereby authorized to appoint such professional parties and approve and/or perform all such other acts and do all such other things as may be necessary for and/or incidental to effecting the above resolutions, including without limitation, complying with directives of any regulatory authority as well as the increase in the Company's Issued Share Capital and consequential amendment of the relevant portion of the Company's Memorandum of Association upon completion of the capital raise.



Chinenye Adekanmbi
Company Secretary